GSK-3 inhibition by an orally active small molecule increases bone mass in rats.

@article{Marsell2012GSK3IB,
  title={GSK-3 inhibition by an orally active small molecule increases bone mass in rats.},
  author={Richard Marsell and Gregor Sisask and Yvonne Nilsson and Anna K Sundgren-Andersson and Ulf Andersson and Sune Larsson and Olle Nilsson and Osten Ljunggren and Kenneth B. Jonsson},
  journal={Bone},
  year={2012},
  volume={50 3},
  pages={619-27}
}
Glycogen synthase kinase 3β (GSK-3β) actions are central in the canonical Wnt pathway, important in many biological processes and a potential drug target for treating several diseases. It is appreciated that a balanced Wnt canonical signaling is crucial for the maintenance of normal bone mass. In this study we investigated the effects of a potent orally active GSK-3 inhibitor, AZD2858, on bone mass in rats. Treatment (1 μM) of human osteoblast cells with AZD2858 in vitro increased β-catenin… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…